CO2017000354A2 - Desmopresina estabilizada - Google Patents

Desmopresina estabilizada

Info

Publication number
CO2017000354A2
CO2017000354A2 CONC2017/0000354A CO2017000354A CO2017000354A2 CO 2017000354 A2 CO2017000354 A2 CO 2017000354A2 CO 2017000354 A CO2017000354 A CO 2017000354A CO 2017000354 A2 CO2017000354 A2 CO 2017000354A2
Authority
CO
Colombia
Prior art keywords
desmopressin
pharmaceutically acceptable
pharmaceutical composition
stabilizing agent
orally disintegrating
Prior art date
Application number
CONC2017/0000354A
Other languages
English (en)
Inventor
Bong Sang Lee
Su-Jun Park
Jiyeong Han
Myeongcheol Kil
Min Seop Kim
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53510836&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2017000354(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of CO2017000354A2 publication Critical patent/CO2017000354A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Abstract

La invención se refiere a una composición farmacéutica que comprende un principio activo y un agente estabilizador, en donde el principio activo es desmopresina o una sal aceptable para uso farmacéutico de la misma, y en donde el agente estabilizador es al menos una goma, el uso de una o más gomas para incrementar la estabilidad de una composición farmacéutica que comprende desmopresina o una sal aceptable para uso farmacéutico de la misma como un principio activo frente a la desnaturalización, un método para preparar una película de desintegración por vía oral que comprende desmopresina o una sal aceptable para uso farmacéutico de la misma así como una película de desintegración por vía oral obtenible de ese modo.
CONC2017/0000354A 2014-06-16 2017-01-16 Desmopresina estabilizada CO2017000354A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020140073067A KR20150144209A (ko) 2014-06-16 2014-06-16 안정화된 데스모프레신 또는 이의 약학적으로 허용가능한 염을 함유 약학 조성물
PCT/EP2015/063347 WO2015193246A1 (en) 2014-06-16 2015-06-15 Stabilized desmopressin

Publications (1)

Publication Number Publication Date
CO2017000354A2 true CO2017000354A2 (es) 2017-03-31

Family

ID=53510836

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0000354A CO2017000354A2 (es) 2014-06-16 2017-01-16 Desmopresina estabilizada

Country Status (34)

Country Link
US (1) US20170128521A1 (es)
EP (1) EP3154516B1 (es)
JP (1) JP6615130B2 (es)
KR (2) KR20150144209A (es)
CN (1) CN106456706B (es)
AR (1) AR100850A1 (es)
AU (1) AU2015276247C1 (es)
BR (1) BR112016029417A8 (es)
CA (1) CA2951768C (es)
CL (1) CL2016003219A1 (es)
CO (1) CO2017000354A2 (es)
DK (1) DK3154516T3 (es)
EA (1) EA032834B1 (es)
ES (1) ES2751600T3 (es)
HR (1) HRP20191746T1 (es)
HU (1) HUE045395T2 (es)
IL (1) IL249538A0 (es)
JO (1) JO3500B1 (es)
LT (1) LT3154516T (es)
MX (1) MX2016016635A (es)
MY (1) MY182781A (es)
NZ (1) NZ727388A (es)
PH (1) PH12016502527A1 (es)
PL (1) PL3154516T3 (es)
PT (1) PT3154516T (es)
RS (1) RS59449B1 (es)
SA (1) SA516380492B1 (es)
SG (2) SG10201811139UA (es)
SI (1) SI3154516T1 (es)
TN (1) TN2016000561A1 (es)
TW (1) TWI670070B (es)
UA (1) UA119776C2 (es)
WO (1) WO2015193246A1 (es)
ZA (1) ZA201608020B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114432424B (zh) * 2021-12-27 2023-06-27 南通联亚药业股份有限公司 一种稳定的铝塑包装去氨加压素片剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE60941B1 (en) * 1986-07-10 1994-09-07 Elan Transdermal Ltd Transdermal drug delivery device
JP2006502972A (ja) * 2002-05-07 2006-01-26 フェリング ベスローテン フェンノートシャップ デスモプレシンの口腔内分散性医薬製剤
GB0210397D0 (en) * 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
WO2007083323A2 (en) * 2006-01-23 2007-07-26 Panacea Biotec Limited. Modified release oral dosage form comprising desmopressin
CN100463674C (zh) * 2006-12-22 2009-02-25 江苏奥赛康药业有限公司 一种氯雷他定口腔速溶膜及其制备方法
TW201422254A (zh) * 2012-11-21 2014-06-16 Ferring Bv 用於速釋及延釋的組成物
US20150306170A1 (en) * 2012-11-21 2015-10-29 Ferring B.V. Composition for immediate and extended release

Also Published As

Publication number Publication date
AU2015276247A1 (en) 2017-02-02
CA2951768A1 (en) 2015-12-23
KR20170020450A (ko) 2017-02-22
JP2017523955A (ja) 2017-08-24
AU2015276247B2 (en) 2019-09-12
KR102360656B1 (ko) 2022-02-09
CN106456706B (zh) 2020-07-14
PT3154516T (pt) 2019-12-05
JP6615130B2 (ja) 2019-12-04
UA119776C2 (uk) 2019-08-12
ZA201608020B (en) 2020-05-27
EA032834B1 (ru) 2019-07-31
IL249538A0 (en) 2017-02-28
MY182781A (en) 2021-02-05
CL2016003219A1 (es) 2017-06-30
SA516380492B1 (ar) 2021-02-03
CN106456706A (zh) 2017-02-22
RS59449B1 (sr) 2019-11-29
EA201692556A1 (ru) 2017-04-28
TN2016000561A1 (en) 2018-04-04
TW201605464A (zh) 2016-02-16
SI3154516T1 (sl) 2019-11-29
PH12016502527B1 (en) 2017-04-10
ES2751600T3 (es) 2020-04-01
MX2016016635A (es) 2017-06-06
HRP20191746T1 (hr) 2019-12-27
LT3154516T (lt) 2019-10-25
NZ727388A (en) 2021-07-30
JO3500B1 (ar) 2020-07-05
HUE045395T2 (hu) 2019-12-30
EP3154516B1 (en) 2019-09-04
PL3154516T3 (pl) 2020-08-10
BR112016029417A8 (pt) 2021-06-29
AU2015276247C1 (en) 2020-02-06
BR112016029417A2 (pt) 2017-08-22
KR20150144209A (ko) 2015-12-24
WO2015193246A1 (en) 2015-12-23
SG10201811139UA (en) 2019-01-30
EP3154516A1 (en) 2017-04-19
TWI670070B (zh) 2019-09-01
US20170128521A1 (en) 2017-05-11
CA2951768C (en) 2022-08-30
DK3154516T3 (da) 2019-09-23
PH12016502527A1 (en) 2017-04-10
AR100850A1 (es) 2016-11-02
SG11201609374YA (en) 2017-01-27

Similar Documents

Publication Publication Date Title
CL2016001874A1 (es) Forma de dosificación oral sólida de liberación modificada que comprende pridopidina y un excipiente de control de velocidad; formulación farmacéutica que comprende a la forma de dosificación; uso de la forma de dosificación o de la formulación farmacéutica para tratar una enfermedad neurodegenerativa o relacionada con dopamina, como la enfermedad de huntington, entre otras.
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CL2018001199A1 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
AR104984A1 (es) Compuestos selectivos para pyy y sus usos
DOP2017000307A (es) Formulación sólida oral que contiene irinotecán y método de preparación de la misma.
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
CO2016003340A2 (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
AR100453A1 (es) Composiciones para el cuidado oral que contienen polietilenglicol para estabilidad física
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
AR106559A1 (es) Suspensión acuosa para administración oral y método para su preparación
CO2017000354A2 (es) Desmopresina estabilizada
BR112017008835A2 (pt) composto, e, composição farmacêutica.
EA201992844A1 (ru) Новые пероральные составы на основе белиностата
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза
EA201890477A1 (ru) Инкапсулированная композиция финголимода
AR099405A1 (es) Composición antifúngica tópica para el tratamiento de onicomicosis
CO2020006552A2 (es) Composiciones farmaceuticas que comprenden safinamida
CY1119636T1 (el) Φαρμακευτικο παρασκευασμα με βαση διοσμεκτιτη
PE20170201A1 (es) Formas de dosificacion farmaceutica
UA115290U (xx) Композиція у формі спрею для орального застосування, що містить холіну альфосцерат
MX2018007272A (es) Composicion farmaceutica de liberacion pulsatil que comprende naftazona o una de sus sales.
MY187299A (en) An extract of tinospora crispa and use as an antihypercholesterolemic agent